Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1060-1070

  Milanovic, Mina ^a   Radtke, Simone ^a   Peel, Nick ^a   Howell, Michael ^a   Carrière, Virginie ^b   Joffre, Carine ^b   Kermorgant, Stéphanie ^b   Parker, Peter J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

aurintricarboxylic acid; c Met; HGF; migration; signalling

Indexed keywords

AURINTRICARBOXYLIC ACID; SCATTER FACTOR RECEPTOR;

ALLOSTERISM; ARTICLE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; AURINTRICARBOXYLIC ACID; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; HELA CELLS; HUMANS; KINESIN; LUNG NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84155165040     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26066     Document Type: Article

References (32)

1. Stoker M, Gherardi E, Perryman M, Gray J,. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327: 239-42. (Pubitemid 17071053)
2. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S,. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3. (Pubitemid 19277521)
3. Trusolino L, Comoglio PM,. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289-300. (Pubitemid 37328782)
4. Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, Nicotra MR, Prat M, Maggi G, Arena N, Natali PG, Comoglio PM, Di Renzo MF,. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 1862-8. (Pubitemid 27007128)
5. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59: 307-10. (Pubitemid 29048858)
6. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF,. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25. (Pubitemid 37493640)
7. Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, Gherardi E,. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 1999; 6: 72-9. (Pubitemid 29232427)
8. Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM,. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 1991; 266: 19558-64. (Pubitemid 21908266)
9. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM,. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261-71. (Pubitemid 24138623)
10. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W,. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384: 173-6. (Pubitemid 26386473)
11. Kermorgant S, Zicha D, Parker PJ,. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem 2003; 278: 28921-9. (Pubitemid 36935802)
12. Kermorgant S, Zicha D, Parker PJ,. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 2004; 23: 3721-34. (Pubitemid 39389704)
13. Kermorgant S, Parker PJ,. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008; 182: 855-63.
14. Gennerich A, Vale RD,. Walking the walk: how kinesin and dynein coordinate their steps. Curr Opin Cell Biol 2009; 21: 59-67.
15. Batut J, Howell M, Hill CS,. Kinesin-mediated transport of Smad2 is required for signaling in response to TGF-beta ligands. Dev Cell 2007; 12: 261-74. (Pubitemid 46172913)
16. Lalli G, Gschmeissner S, Schiavo G,. Myosin Va and microtubule-based motors are required for fast axonal retrograde transport of tetanus toxin in motor neurons. J Cell Sci 2003; 116: 4639-50. (Pubitemid 37461618)
17. Hopkins SC, Vale RD, Kuntz ID,. Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 2000; 39: 2805-14. (Pubitemid 30148936)
18. Bouchard P, Penningroth SM, Cheung A, Gagnon C, Bardin CW,. erythro-9-[3-(2-Hydroxynonyl)]adenine is an inhibitor of sperm motility that blocks dynein ATPase and protein carboxylmethylase activities. Proc Natl Acad Sci USA 1981; 78: 1033-6. (Pubitemid 11100764)
19. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake RA, Howlett AR, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2003; 2: 1085-92.
20. Cho H, Lee DY, Shrestha S, Shim YS, Kim KC, Kim MK, Lee KH, Won J, Kang JS,. Aurintricarboxylic acid translocates across the plasma membrane, inhibits protein tyrosine phosphatase and prevents apoptosis in PC12 cells. Mol Cell 2004; 18: 46-52. (Pubitemid 39386654)
21. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R,. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003; 63: 5462-9. (Pubitemid 37139865)
22. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 352-61. (Pubitemid 43166042)
23. Okada N, Koizumi S,. A neuroprotective compound, aurin tricarboxylic acid, stimulates the tyrosine phosphorylation cascade in PC12 cells. J Biol Chem 1995; 270: 16464-9.
24. Okada N, Koizumi S,. Tyrosine phosphorylation of ErbB4 is stimulated by aurintricarboxylic acid in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 1997; 230: 266-9. (Pubitemid 27211981)
25. Beery R, Haimsohn M, Wertheim N, Hemi R, Nir U, Karasik A, Kanety H, Geier A,. Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue. Endocrinology 2001; 142: 3098-107. (Pubitemid 32575548)
26. Antipova AA, Stockwell BR, Golub TR,. Gene expression-based creening for inhibitors of PDGFR signaling. Genome Biol 2008; 9: R47.
27. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J,. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125: 1137-49. (Pubitemid 43866200)
28. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43. (Pubitemid 46799492)
29. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL,. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25. (Pubitemid 41039112)
30. Kermorgant S, Jonna N, Ivaska J,. Smart targeting of EGFR in lung cancer. Pharmacogenomics 2010; 11: 743-6.
31. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24: 1195-203. (Pubitemid 46638818)
32. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J,. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010; 70: 1625-34.